Literature DB >> 7643909

The antinociception induced by beta-endorphin administered intrathecally is mediated by the activation of mu- and kappa-opioid receptors in the rat.

L F Tseng1, B Henneberry, K A Collins.   

Abstract

The antinociception induced by beta-endorphin given supraspinally has been previously demonstrated to be mediated by the stimulation of epsilon-, but not mu-, delta- or kappa-opioid receptors in rats and mice. The present study was designed to determine what types of opioid receptors in the spinal cord are involved in the antinociception induced by intrathecally (i.t.) administered beta-endorphin. Antinociception was assessed by the tail-flick test in male Sprague-Dawley rats. CTOP (0.9-6.6 nmol), a selective mu-opioid receptor antagonist, or nor-BNI(13.6-95.3 nmol), a selective kappa-opioid receptor antagonist, given i.t. dose-dependently reversed i.t. administered beta-endorphin-induced inhibition of the tail-flick response. On the other hand, naltrindole (6.6-44.4 nmol), a selective delta-opioid receptor antagonist, or beta-endorphin (1-27) (1-6.7 nmol), a selective epsilon-opioid receptor antagonist given i.t., did not antagonize the inhibition of the tail-flick response induced by i.t. administered beta-endorphin. The results are consistent with the previous study in mice [Tseng LF and Collins KA (1992) Eur J Pharmacol 214: 59-65] that the antinociception induced by beta-endorphin given i.t. is mediated by the stimulation of mu- and kappa-, but not delta- and epsilon-opioid receptors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7643909     DOI: 10.1007/bf00171036

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  25 in total

1.  Central effects of the potent and highly selective mu opioid antagonist D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP) in mice.

Authors:  K Gulya; M Kriván; N Nyolczas; Z Sarnyai; G L Kovács
Journal:  Eur J Pharmacol       Date:  1988-06-10       Impact factor: 4.432

2.  Opioid delta-receptor involvement in supraspinal and spinal antinociception in mice.

Authors:  J S Heyman; S A Mulvaney; H I Mosberg; F Porreca
Journal:  Brain Res       Date:  1987-09-08       Impact factor: 3.252

3.  The role of amino-terminal sequence of beta-endorphin and dynorphin in the determination of opiate receptor type selectivity.

Authors:  J K Chang; K J Chang
Journal:  Life Sci       Date:  1983       Impact factor: 5.037

4.  C-fragment of lipotropin--an endogenous potent analgesic peptide.

Authors:  W Feldberg; D G Smyth
Journal:  Br J Pharmacol       Date:  1977-07       Impact factor: 8.739

5.  Binding of 3H-beta-endorphin in rat brain.

Authors:  N Johnson; R Houghten; G W Pasternak
Journal:  Life Sci       Date:  1982 Sep 20-27       Impact factor: 5.037

6.  Chronic catheterization of the spinal subarachnoid space.

Authors:  T L Yaksh; T A Rudy
Journal:  Physiol Behav       Date:  1976-12

7.  Antinociceptive effects of intrathecally administered human beta-endorphin in the rat and cat.

Authors:  T L Yaksh; J L Henry
Journal:  Can J Physiol Pharmacol       Date:  1978-10       Impact factor: 2.273

8.  Nor-binaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays.

Authors:  A E Takemori; B Y Ho; J S Naeseth; P S Portoghese
Journal:  J Pharmacol Exp Ther       Date:  1988-07       Impact factor: 4.030

9.  Beta-endorphin-(1-27) antagonizes beta-endorphin- but not morphine-, D-Pen2-D-Pen5-enkephalin- and U50, 488H-induced analgesia in mice.

Authors:  H H Suh; L F Tseng; C H Li
Journal:  Neuropharmacology       Date:  1988-09       Impact factor: 5.250

10.  Involvement of central mu and delta opioid receptors in mediating the reinforcing effects of beta-endorphin in the rat.

Authors:  R Bals-Kubik; T S Shippenberg; A Herz
Journal:  Eur J Pharmacol       Date:  1990-01-03       Impact factor: 4.432

View more
  1 in total

1.  The Neuropeptide Systems and their Potential Role in the Treatment of Mammalian Retinal Ischemia: A Developing Story.

Authors:  D Cervia; G Casini
Journal:  Curr Neuropharmacol       Date:  2013-01       Impact factor: 7.363

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.